|
David Guy joined Favrille with 18 years of experience in marketing and sales, including more than 10 years specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan®, Herceptin®, Fludara® and Taxotere®. Prior to joining Favrille, Mr. Guy served as Vice President, Global Strategic Marketing and Business Development, Oncology at Schering AG/Berlex. Previously, he served as Director, Oncology Marketing at Genentech, where he was responsible for the marketing activities for both Rituxan and Herceptin. Prior to Genentech, Mr. Guy spent six years at Sanofi-Aventis as U.S. Business Unit Head, Oncology (Sanofi), and held several key commercial positions that contributed to the success of Taxotere (Aventis/RPR). Mr. Guy earned his Bachelor of Science degree in Biology with a specialization in Molecular Genetics from McMaster University in Hamilton, Ontario. | 